Baseline cytokine levels may predict the development of immune-mediated adverse events following immunotherapy

The development of immunotherapy is one of the greatest advances in cancer treatment, but up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs) and up to 80% of individuals receiving checkpoint inhibitors experience some form of irAE. Predicting which patients will react negatively in response to immunotherapy